Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1999-10-15
pubmed:abstractText
1. We investigated the effects of recombinant human erythropoietin (rh-EPO) in splanchnic artery occlusion (SAO) shock. Sham operated animals were used as controls. Survival rate, mean arterial blood pressure (MAP), serum Tumor Necrosis Factor (TNF-alpha), plasma nitrite/nitrate concentrations, red blood cell (RBC) count, blood haemoglobin (Hb), the responsiveness of aortic rings to phenylephrine (PE, 1 nM-10 microM) and the activity of inducible nitric oxide synthase (iNOS) were studied. 2. SAO shocked rats had a decreased survival rate (0% at 4 h of reperfusion, while sham shocked rats survived more than 4 h), enhanced serum TNF-alpha concentrations, increased plasma nitrite/nitrate levels (60+/-9.5 microM; sham shocked rats= 2+/-0.4 microM), decreased MAP, unchanged RBC count and blood Hb and enhanced iNOS activity in the aorta. Moreover aortic rings from shocked rats showed a marked hyporeactivity to PE. 3. Rh-EPO (25, 50 and 100 U 100 g(-1), 5 min following the onset of reperfusion) increased survival rate (70% at 4 h of reperfusion with the highest dose), reduced plasma nitrite/nitrate concentrations (10.3+/-3.3 microM), increased MAP, did not change RBC count and blood Hb, and inhibited iNOS activity in thoracic aortae. Furthermore rh-EPO, either in vivo or in vitro (10 U for 1 h in the organ bath), restored to control values the hyporeactivity to PE. Finally rh-EPO inhibited the activity of iNOS in peritoneal macrophages activated with endotoxin. 4. Our data suggest that rh-EPO protects against SAO shock by inhibiting iNOS activity.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-14117598, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-1504736, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-1557429, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-1852778, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-2002640, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-2017231, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-3139757, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-3542810, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-3680293, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-4931294, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-7441497, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-7537167, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-7678341, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-7858885, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-7889268, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-8289996, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-8307893, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-8619882, http://linkedlifedata.com/resource/pubmed/commentcorrection/10385249-8872352
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
127
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
482-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:10385249-Animals, pubmed-meshheading:10385249-Aorta, Thoracic, pubmed-meshheading:10385249-Blood Pressure, pubmed-meshheading:10385249-Constriction, Pathologic, pubmed-meshheading:10385249-Enzyme Inhibitors, pubmed-meshheading:10385249-Erythrocyte Count, pubmed-meshheading:10385249-Erythropoietin, pubmed-meshheading:10385249-Humans, pubmed-meshheading:10385249-Male, pubmed-meshheading:10385249-Muscle, Smooth, Vascular, pubmed-meshheading:10385249-Muscle Contraction, pubmed-meshheading:10385249-Nitric Oxide, pubmed-meshheading:10385249-Nitric Oxide Synthase, pubmed-meshheading:10385249-Nitric Oxide Synthase Type II, pubmed-meshheading:10385249-Rats, pubmed-meshheading:10385249-Rats, Sprague-Dawley, pubmed-meshheading:10385249-Recombinant Proteins, pubmed-meshheading:10385249-Shock, pubmed-meshheading:10385249-Splanchnic Circulation, pubmed-meshheading:10385249-Survival Analysis, pubmed-meshheading:10385249-Tumor Necrosis Factor-alpha
pubmed:year
1999
pubmed:articleTitle
Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.
pubmed:affiliation
Institute of Pharmacology, School of Medicine, University of Messina, Italy. squadrito@csnet.it
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't